Vimseltinib

Vimseltinib
Clinical data
Trade names	Romvimza
License data	US DailyMed: Vimseltinib;
Routes of; administration	By mouth
Drug class	Antineoplastic
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one;
CAS Number	1628606-05-2;
PubChem CID	86267612;
IUPHAR/BPS	11190;
DrugBank	DB17520;
ChemSpider	95499700;
UNII	PX9FTM69BF;
KEGG	D12238;
ChEMBL	ChEMBL5095202;
Chemical and physical data
Formula	C23H25N7O2
Molar mass	431.500 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC(=N1)C2=CN=C(N(C2=O)C)NC(C)C)OC3=CC(=NC=C3)C4=CN(N=C4)C;
	InChI InChI=1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27); Key:TVGAHWWPABTBCX-UHFFFAOYSA-N;

Vimseltinib, sold under the brand name Romvimza, is an anti-cancer medication used for the treatment of tenosynovial giant cell tumor. Vimseltinib is a kinase inhibitor. Vimseltinib is a macrophage colony-stimulating factor receptor antagonist.

The most common adverse reactions, including laboratory abnormalities, include increased aspartate aminotransferase, periorbital edema, fatigue, rash, increased cholesterol, peripheral edema, face edema, decreased neutrophils, decreased leukocytes, pruritus, and increased alanine aminotransferase.

Vimseltinib was approved for medical use in the United States in February 2025.